ATP-citrate lyase: a key player in cancer metabolism.
ATP-citrate lyase (ACLY) is a cytosolic enzyme that catalyzes the generation of acetyl CoA from citrate. Acetyl CoA is a vital building block for the endogenous biosynthesis of fatty acids and cholesterol and is involved in isoprenoid-based protein modifications. Acetyl CoA is also required for acetylation reactions that modify proteins, such as histone acetylation. ACLY is upregulated or activated in several types of cancers, and its inhibition is known to induce proliferation arrest in cancer cells both in vitro and in vivo. The present review highlights current knowledge about the role of ACLY in cancer cells, with special reference to the different pathways that are linked by ACLY.
Department of Oncology, Janssen Research and Development, a division of Janssen Pharmaceutica, Beerse, Belgium.
Nousheen
N
Zaidi
Johannes V
JV
Swinnen
Karine
K
Smans
D001275:ATP Citrate (pro-S)-Lyase / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D005973:Glutamine / Q000378:metabolism; D006801:Humans; D053858:Metabolic Networks and Pathways / Q000235:genetics / Q000502:physiology; D008798:Mevalonic Acid / Q000378:metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology
D005227:Fatty Acids; D005973:Glutamine; D001275:ATP Citrate (pro-S)-Lyase; D005947:Glucose; D008798:Mevalonic Acid